Targeted antiviral platform Decoy Therapeutics is building Designable Multi-Antivirals (D-MAVs) designed to work across multiple viruses, offering a broad-spectrum appeal that could reduce the number of separate antiviral programs a partner needs to pursue.

AI powered speed The IMP³ACT platform combines AI-enabled design with rapid peptide synthesis to accelerate preclinical progress, creating opportunities for faster collaboration timelines and earlier joint milestones with potential partners.

Clinical development readiness Strategic development initiatives aim to advance lead D-MAV candidates into Phase 1/2a, signaling a near-term path to human proof-of-concept that can attract pharma collaborators seeking early-stage access to novel antiviral modalities.

Clinical development partnerships Decoy has engaged hVIVO Group for translational modeling, regulatory strategy, and Phase 1/2a study preparation, presenting a ready-made collaboration framework for partners interested in shared clinical development responsibilities.

Executive and scientific oversight With a recent appointment of a prominent academic chair to the Scientific Advisory Board, there is an emphasis on credibility and strategic guidance that can reassure potential partners of rigorous scientific stewardship and long-term roadmap alignment.